Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery for Diabetes and Obesity

Novo Nordisk, the world's leading diabetes and obesity drug maker, announced on April 14 a strategic partnership with OpenAI to integrate advanced AI throughout its drug development pipeline. CEO Mike Doustdar stated the collaboration enables the company to 'analyse datasets at a scale that was previously impossible,' dramatically accelerating the identification of drug candidates for chronic diseases like diabetes and obesity — conditions affecting over 800 million people globally. The partnership will apply OpenAI's large language and reasoning models to molecular biology datasets, clinical trial data analysis, and biomarker identification. This follows a trend of major pharmaceutical companies forming AI-first drug discovery alliances, though the Novo Nordisk-OpenAI partnership is notable for targeting diseases affecting primarily lower- and middle-income countries and populations in the Global South where affordable treatment remains inaccessible.